The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

Novo Nordisk (NVO) stock popped to a record high Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients.

The company tested three oral doses of semaglutide. The highest doses — 25 milligrams and 50 milligrams — led to greater reductions in body weight and blood sugar than the already approved 14-milligram dose. Novo Nordisk's study took place over a year in patients with type 2 diabetes.